Potential drug interactions associated with treatments for Type 2 diabetes and its comorbidities: A clinical pharmacology review

Expert Review of Clinical Pharmacology

Volumn 5, Issue 1, 2012, Pages 31-42

  Freeman, Jeffrey S ^a   Gross, Benjamin ^b  

^a PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

comorbidities; drug interactions; polypharmacy; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIPROFLOXACIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GEMFIBROZIL; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; INSULIN; ITRACONAZOLE; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; MONOAMINE OXIDASE INHIBITOR; NATEGLINIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SALICYLIC ACID DERIVATIVE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; UNINDEXED DRUG; VILDAGLIPTIN;

COMORBIDITY; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; CYANOCOBALAMIN DEFICIENCY; DIABETIC PATIENT; DRUG DOSE REDUCTION; DRUG METABOLISM; FLUID RETENTION; FRACTURE; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; HYPOGLYCEMIA; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOLYSIS; POLYPHARMACY; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SECONDARY OSTEOPOROSIS; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

ANIMALS; ANTIHYPERTENSIVE AGENTS; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; DYSLIPIDEMIAS; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; PHARMACOLOGY, CLINICAL;

EID: 83055163356     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.11.64     Document Type: Review

References (93)

1. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N. Engl. J. Med. 348, 383-393 (2003).
2. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in Type 2 diabetes. N. Engl. J. Med. 358, 580-591 (2008).
3. Holt RI, Phillips DI, Jameson KA, Cooper C, Dennison EM, Peveler RC. The relationship between depression and diabetes mellitus: findings from the Hertfordshire cohort study. Diabetes Med. 26, 641-648 (2009).
4. Campayo A, de Jonge P, Roy JF et al. Depressive disorder and incident diabetes mellitus: The effect of characteristics of depression. Am. J. Psychiatry 167, 580-588 (2010).
5. Gale CR, Kivimaki M, Lawlor DA, Carroll D, Phillips AC, Batty GD. Fasting glucose, diagnosis of Type 2 diabetes, and depression: the Vietnam experience study. Biol. Psychiatry 67, 189-192 (2010).
6. Knol MJ, Heerdink ER, Egberts AC et al. Depressive symptoms in subjects with diagnosed and undiagnosed Type 2 diabetes. Psychosom. Med. 69, 300-305 (2007).
7. Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and Type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 31, 2383-2390 (2008).
8. Collins MM, Corcoran P, Perry IJ. Anxiety and depression symptoms in patients with diabetes. Diabetes Med. 26, 153-161 (2009).
9. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 3, 169-178 (2004).
10. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol. 61, 661-666 (2004).
11. Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN. Polypharmacy: misleading, but manageable. Clin. Interv. Aging 3, 383-389 (2008).
12. Willlams CM. Using medications appropriately in older adults. Am. Fam. Phys. 66, 1917-1924 (2002).
13. Rodbard HW, Jellinger PS, Davidson JA et al. Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology consensus panel on Type 2 diabetes mellitus: an algorithm for glycemic control. Endocr. Pract. 15, 540-559 (2009).
14. Holstein A, Beil W. Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions. Exp. Opin. Drug Metab. Toxicol. 5, 225-241 (2009).
15. Holstein A, Hahn M, Patzer O, Seeringer A, Kovacs P, Stingl J. Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. Eur. J. Clin. Pharmacol. 67, 471-476 (2011).
16. Scheen AJ. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin. Pharmacokinet. 46, 93-108 (2007).
17. Weiss J, Sauer A, Herzog M, Boger RH, Haefeli WE, Benndorf RA. Interaction of thiazolidinediones (glitazones) with the ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein. Pharmacology 84, 264-270 (2009).
18. Scheen AJ. Dipeptidylpeptitase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin. Pharmacokinet. 49, 573-588 (2010).
19. Wang C, Li J, Lv X et al. Ameliorative effect of berberine on endothelial dysfunction in diabetic rats induced by high-fat diet and streptozotocin. Eur. J. Pharmacol. 620, 131-137 (2009).
20. Thomas MC, Atkins RC. Blood pressure lowering for the prevention and treatment of diabetic kidney disease. Drugs 66, 2213-2234 (2006).
21. Centers for Disease Control and Prevention. Morbidity and mortality weekly report: incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetes - United States and Puerto Rico, 1996-2007 MMWR Morb. Mortal Wkly Rep. 59(42), 1361-1366 (2010).
22. Gilbert RE, Cooper ME, Krum H. Drug administration in patients with diabetes mellitus. Safety considerations. Drug Saf. 18, 441-455 (1998).
23. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 19, 403-418 (1992).
24. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin- receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med. 345, 851-860 (2001).
25. Bell DS. Metformin-induced vitamin B12 deficiency presenting as a peripheral neuropathy. South Med. J. 103, 265-267 (2010).
26. Glyburide tablets USP (nonmicronized) 1.25, 2.5 and 5 mg, prescribing information. Sandoz Inc., NJ, USA (2009).
27. Glucotrol® (glipizide), prescribing information. Pfizer, Inc., NY, USA (2010).
28. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 46, 347-351 (2003).
29. Prandin® (repaglinide) tablets (0.5, 1 and 2 mg), prescribing information. Novo Nordisk Inc., Princeton, NJ, USA (2010).
30. Starlix® (nateglinide) tablets, prescribing information. Novartis Pharmaceuticals, East Hanover, NJ, USA (2011).
31. Rodbard HW, Blonde L, Braithwaite SS et al. American association of clinical endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr. Pract. 13(Suppl. 1), S1-S68 (2007).
32. Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet. 35, 361-390 (1998).
33. Scheen AJ. Pharmacokinetic interactions with thiazolidinediones. Clin. Pharmacokinet. 46, 1-12 (2007).
34. Simo R, Rodriguez A, Caveda E. Different effects of thiazolidinediones on cardiovascular risk in patients with Type 2 diabetes mellitus: pioglitazone versus rosiglitazone. Curr. Drug Saf. 5, 234-244 (2010).
35. Lecka-Czernik B. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr. Osteoporos. Rep. 8, 178-184 (2010).
36. Januvia® (sitagliptin) tablets, prescribing information. Merck & Co., Inc., NJ, USA (2010).
37. Onglyza® (saxagliptin) tablets, prescribing information. Bristol-Myers Squibb Company, NJ, USA (2011).
38. Galuvs® (vildagliptin), prescribing information. Novartis Pharmaceuticals Australia Pty Ltd., NSW, Australia (2011).
39. Tradjenta™ (linagliptin), prescribing information. Boehringer Ingelheim Pharmaceuticals Inc, CT, USA (2011).
40. Engel SS, Williams-Herman DE, Golm GT et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int. J. Clin. Pract. 64, 984-990 (2010).
41. Levemir® (insulin detemir [rDNA origin] injection), prescribing information. Novo Nordisk, NJ, USA (2010).
42. Lantus® (insulin glargine [rDNA origin] injection), prescribing information. sanofi-aventis, NJ, USA (2007).
43. Humalog® (insulin lispro injection, USP), prescribing information. Eli Lilly and Company, IN, USA (2011).
44. Apidra® (insulin glulisine [rDNA origin] injection) solution for injection, prescribing information. sanofi-aventis U.S. LLC, NJ, USA (2009).
45. NovoLog® (insulin aspart [rDNA origin] injection), prescribing information. Novo Nordisk, Inc., NJ, USA (2010).
46. Humulin® R (regular U-500 [concentrated] insulin human injection [rDNA origin]), prescribing information. Eli Lilly, IN, USA (2011).
47. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in Type 2 (noninsulin-dependent) diabetic patients. J. Clin. Endocrinol. Metab. 81, 327-332 (1996).
48. Nauck MA,Niedereichholz U, Ettler R et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am. J. Physiol. Endocrinol. Metab. 273, E981-E988 (1997).
49. Byetta® (exenatide) injection, prescribing information. Amylin Pharmaceuticals, Inc., CA, USA (2010).
50. Victoza® (liraglutide [rDNA origin] injection) solution for subcutaneous use, prescribing information. Novo Nordisk, Inc., NJ, USA (2011).
51. Peterson GE, Pollom RD. Liraglutide in clinical practice: dosing, safety and efficacy. Int. J. Clin. Pract. Suppl. 64, 35-43 (2010).
52. Hogue JC, Lamarche B, Deshaies Y et al. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with Type 2 diabetes mellitus with marked hypertriglyceridemia. Metabolism 57, 246-254 (2008).
53. Ballantyne CM, Corsini A, Davidson MH et al. Risk for myopathy with statin therapy in high-risk patients. Arch. Intern. Med. 163, 553-564 (2003).
54. Paoletti R, Corsini A, Bellosta S. Pharmacological interactions of statins. Atheroscler. Suppl. 3, 35-40 (2002).
55. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther. 80, 565-581 (2006).
56. Amsden GW, Kuye O, Wei GC. A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. J. Clin. Pharmacol. 42, 442-449 (2002).
57. Lau YY, Huang Y, Frassetto L, Benet LZ. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin. Pharmacol .Ther. 81, 194-204 (2007).
58. Guay DR. Update on fenofibrate. Cardiovasc. Drug Rev. 20, 281-302 (2002).
59. Brautbar A, Covarrubias D, Belmont J et al. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis doi:10.1016/j.atherosclerosis.2011.08.015 (2011) (Epub ahead of print).
60. Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849-1861 (2005).
61. Pruski M, Krysiak R, Okopien B. Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in Type 2 diabetic patients with mixed dyslipidemia. Diabetes Care 32, 1421-1424 (2009).
62. Agouridis AP, Filippatos TD, Derdemezis CS, Mikhailidis DP, Elisaf MS. Combination of fenofibrate with non-statin drug regimens. Curr. Pharm. Des. 16, 3401-3416 (2010).
63. Triglide® (fenofibrate) tablets, prescribing information. Shionogi Pharma Inc., GA, USA (2010).
64. King JM, Crouse JR, Terry JG, Morgan TM, Spray BJ, Miller NE. Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia. Am. J. Med. 97, 323-331 (1994).
65. Vijayaraghavan K, Deedwania P. Renin- angiotensin-aldosterone blockade for cardiovascular disease prevention. Cardiol. Clin. 29, 137-156 (2011).
66. Alsheikh-Ali AA, Karas RH. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system). Am. J. Cardiol. 99, 379-381 (2007).
67. Bell DS. Treatment of diabetic hypertension. Diabetes Obes. Metab. 11, 433-444 (2009).
68. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotection effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A seven year follow-up study. Arch. Intern. Med. 156, 286-289 (1996).
69. Chaturvedi N, Sjolie AK, Stephenson JM et al. Effect of lisinopril on progression of retinopathy in normotensive people with Type 1 diabetes. The EUCLID Study Group. EURODIAB controlled trial of lisinopril in insulin-dependent diabetes mellitus. Lancet 351, 28-31 (1998).
70. McLaughlin DM, Atkinson AB, Ennis CN et al. Comparison of effects of combined ACE inhibitor and low-dose thiazide diuretic with ACE inhibitor alone on insulin action in patients with hypertension and Type 2 diabetes: a double-blind crossover study. Diabetes Med. 25, 631-634 (2008).
71. Marcum ZA, Fried LF. Aging and antihypertensive medication-related complications in the chronic kidney disease patient. Curr. Opin. Nephrol. Hypertens. 20, 449-456 (2011).
72. Packham DK, Ivory SE, Reutens AT et al. Proteinuria in Type 2 diabetic patients with renal impairment: the changing face of diabetic nephropathy. Nephron Clin. Pract. 118, c331-c338 (2011).
73. Juhlin T, Erhardt LR, Ottosson H, Jonsson BA, Hoglund P. Treatments with losartan or enalapril are equally sensitive to deterioration in renal function from cyclooxygenase inhibition. Eur. J. Heart Fail. 9, 191-196 (2007).
74. Deferrari G, Ravera M, Berruti V, Leoncini G, Deferrari L. Optimizing therapy in the diabetic patient with renal disease: antihypertensive treatment. J. Am. Soc. Nephrol. 15 (Suppl. 1), S6-S11 (2004).
75. Avapro® (irbesartan) tablets, prescribing information. Bristol-Myers Squibb, NY, USA (2007).
76. Cozaar® (losartan potassium tablets), prescribing information. Merck & Co., Inc., NJ, USA (2011).
77. Bakris GL, Fonseca V, Katholi RE et al. Metabolic effects of carvedilol vs metoprolol in patients with Type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292, 2227-2236 (2004).
78. Tenormin® (atenolol), prescribing information. Astra Zeneca Pharmaceuticals, LP, DE, USA (2011).
79. Coreg® (carvedilol) tablets, prescribing information. GlaxoSmithKline, Research Triangle Park, NC, USA (2011).
80. Fonseca VA. Effects of b-blockers on glucose and lipid metabolism. Curr. Med. Res. Opin. 26, 615-629 (2010).
81. Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann. Intern. Med. 122, 133-141 (1995).
82. Calan® verapamil hydrochloride tablets, prescribing information. Pfizer Inc., NY, USA (2009).
83. Procardia® (nifedipine) capsules for oral use, prescribing information. Pfizer Inc., NY, USA (2011).
84. Zocor® (simvastatin), prescribing information. Merck & Co., Inc., Whitehouse Station, NJ, USA (2011).
85. Mevacor® (lovastatin), prescribing information. Merck & Co., Inc., Whitehouse Station, NJ, USA (2010).
86. Lasix® (furosemide) tablets 20, 40, and 80 mg, prescribing information. sanofi-aventis, NJ, USA (2011).
87. Duarte JD, Cooper-DeHoff RM. Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Exp. Rev. Cardiovasc. Ther. 8(6), 793-802 (2010).
88. Schneider M, Lerch M, Papiri M et al. Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive Type 2 diabetes. J. Hypertens. 14, 669-677 (1996).
89. Lin G, Hays DP, Spillane L. Refractory hypoglycemia from ciprofloxacin and glyburide interaction. J. Toxicol. Clin. Toxicol. 42, 295-297 (2004).
90. Mehlhorn AJ, Brown DA. Safety concerns with fluoroquinolones. Ann. Pharmacother. 41, 1859-1866 (2007).
91. Brown TT, Cole SR, Li X et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch. Intern. Med. 165, 1179-1184 (2005).
92. Spollett GR. Hyperglycemia in HIV/ AIDS. Diabetes Spectr. 19, 163-166 (2006).
93. Crixivan® (indinavir sulfate) capsules, prescribing information. Merck & Co., Inc., NJ, USA (2010).